Patients hospitalized with COVID-19 are at a higher risk of thrombotic events following
discharge, however the role of extended thromboprophylaxis remains controversial. The …

Background: Data are limited regarding the incidence of thromboembolism post-hospital
discharge among COVID-19 patients. Guidelines addressing the role of extended …

Background A recent randomized trial, the MICHELLE trial, demonstrated improved
posthospital outcomes with a 35‐day course of prophylactic rivaroxaban for patients …

RATIONALE: Patients with COVID-19 face an elevated risk of developing thromboembolic
events. The incidence of arterial and venous thromboembolism stands at approximately …

Patients with COVID-19 develop an increased risk of thromboembolism.
Thromboprophylaxis is recommended for hospitalized COVID-19 patients, but the role of …

Background Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized
patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of …

Introduction Some local protocols suggest using intermediate or therapeutic doses of
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …

Infection with SARS-CoV-2 virus (COVID-19 disease) is associated with increased levels of
inflammation and hypercoagulability. The risk of thrombosis includes the venous …

Several data demonstrated that the incidence of COVID-19 associated-venous
thromboembolism (VTE) is high [1–4]. However, data regarding rates of VTE after discharge …

Background The effect of extended thromboprophylaxis in improving the prognosis of adult
patients with coronavirus disease 2019 (COVID-19) after discharge remains debatable. This …